Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Íñigo Les, Mireia Martínez, Inés Pérez-Francisco, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1629-1629
Open Access | Times Cited: 43
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao V. Alessi, Biagio Ricciuti, Stephanie Alden, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 11, pp. e003536-e003536
Open Access | Times Cited: 77
Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Wei Zhang, Yifei Tan, Yuquan Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1225-1225
Open Access | Times Cited: 8
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Cheol‐Kyu Park, Hyung‐Joo Oh, Young‐Chul Kim, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1042-1054
Open Access | Times Cited: 19
Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Xinyu Zhang, Bei Zhang, Danfei Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study
Tiphaine Boucheron, Laurent Chiche, Guillaume Pénaranda, et al.
Therapeutics and Clinical Risk Management (2025) Vol. Volume 21, pp. 273-282
Open Access
Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis
Hongrui Lu, Pengfei Zhu, Ya-Ya Deng, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 5, pp. 1106-1116
Closed Access | Times Cited: 9
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
World Journal of Gastrointestinal Oncology (2023) Vol. 15, Iss. 11, pp. 1900-1912
Open Access | Times Cited: 9
Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer
George Raynes, Mark Stares, Samantha Low, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5502-5502
Open Access | Times Cited: 9
Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, et al.
Cancer Diagnosis & Prognosis (2024) Vol. 4, Iss. 1, pp. 34-41
Open Access | Times Cited: 3
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Mar Riveiro‐Barciela, Sabela Carballal, Álvaro Díaz‐González, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 4, pp. 401-432
Open Access | Times Cited: 3
Prognostic significance of baseline neutrophil–lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data
Liliang Huang, Shiyu Jiang, Yuankai Shi
Future Oncology (2022) Vol. 18, Iss. 14, pp. 1679-1689
Closed Access | Times Cited: 11
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study
Airi Fujimoto, Yoshimichi Koutake, Daisuke Hisamatsu, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2169-2178
Open Access | Times Cited: 6
Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
Juyue Zhou, Zhonghai Du, Jie Fu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Mar Riveiro‐Barciela, Sabela Carballal, Álvaro Díaz‐González, et al.
Revista Española de Enfermedades Digestivas (2024)
Open Access | Times Cited: 1
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Mar Riveiro‐Barciela, Sabela Carballal, Álvaro Díaz‐González, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 4, pp. 401-432
Open Access | Times Cited: 1
Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study
Ryota Ozawa, Kei Sonehara, Tsutomu Hachiya, et al.
Cancer Medicine (2024) Vol. 13, Iss. 15
Open Access | Times Cited: 1
Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be Regarding Our Treatment Decisions?
Arife Ulaş, Beyza Temel, Fahriye Tuğba Köş
Medicina (2024) Vol. 60, Iss. 11, pp. 1792-1792
Open Access | Times Cited: 1
Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study
Yingying Jiang, Yue Shi, Yiling Liu, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 12, pp. 2521-2538
Open Access | Times Cited: 6
Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
Hongjian Yang, Yuxi Miao, Zhaojin Yu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Changes in Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio During Palliative Radiotherapy May Predict Efficacy of Immune Checkpoint Inhibitor as Re-Challenge Treatment in Advanced Gastric Cancer: A Case Report
Jianxin Chen, Xi‐Lin Wu, Shijian Zhu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
The Progress of Research on the Roles of NLR, PLR, LMR, and Serum D-Dimer in Predicting the Efficacy of Immunotherapy for Lung Cancer
凤云 马
Advances in Clinical Medicine (2024) Vol. 14, Iss. 05, pp. 734-744
Closed Access
Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities
Mark Stares, Leo R. Brown, Dhruv Abhi, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1508-1508
Open Access
Page 1 - Next Page

Scroll to top